Skip to main content

Table 3 Percentage footpad swelling (%fs) (delayed-type hypersensitivity reaction) to BSA or 18 kDa-hsp M. leprae antigens supported on DODAB-covered silica particles, or complexed with Al(OH3).

From: Silica-based cationic bilayers as immunoadjuvants

Systems for sensitization Ag/dose for sensitization (μg/mouse) Elicitation (μg/mouse)(i)
   BSA 18 kDa-hsp M. leprae
   4 40 3 30
   % footpad swelling ± SEM
Silica/DODAB(ii) - 2 ± 2 2 ± 2 - -
BSA 10 2 ± 2 2 ± 2 - -
Silica/BSA(ii) 10 3 ± 2 2 ± 2 - -
DODAB BF(iii)/BSA 10 3 ± 2 2 ± 2 - -
Silica/DODAB/BSA(ii) 10 11 ± 2(iv) 14 ± 4(iv) - -
18 kDa-hsp M. leprae 15 - - 4 ± 2 10 ± 2
DODAB BF(iii)/18 kDa-hsp 15    56 ± 8(iv), (v) 95 ± 16(iv), (v)
Silica/DODAB/18 kDa-hsp(ii) 15 - - 60 ± 7(iv), (v) 89 ± 8(iv), (v)
Al(OH)3/18 kDa-hsp(ii) 15 - - 18 ± 4(iv) 33 ± 1(iv)
  1. (i) Animals were sensitized with different systems and footpad swelling was elicited on the 5th day pos-immunization.
  2. (ii) Silica at final concentration of 0.1 mg/ml; DODAB at final concentration of 0.05 mM. Al(OH)3 at final concentration of 0.1 mg/ml.
  3. (iii) [DODAB] = 0.1 mM.
  4. (iv) P < 0.05, compared to animals that were BSA or 18 kDa-hsp M. leprae-pretreated and received the same elicitation dose.
  5. (v) P < 0.05, compared to animals that were Al(OH3)/18 kDa-hsp-pretreated and received the same elicitation dose.